Prostate Cancer, Advanced or Metastatic

References

Citations

1. Gronberg H (2003). Prostate cancer epidemiology. Lancet, 361(9360): 859–864.

2. American Cancer Society (2005). Cancer Facts and Figures 2005, pp. 1–60. Atlanta: American Cancer Society. Available online: http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts__Figures_2005.asp.

3. Frankel S, et al. (2003). Screening for prostate cancer. Lancet, 361(9363): 1122–1128.

4. National Cancer Institute (2005). Prostate Cancer (PDQ): Prevention—Health Professional Version. Available online: http://www.nci.nih.gov/cancertopics/pdq/prevention/prostate/HealthProfessional/page3.

5. Kantoff PW (2005). Prostate cancer. In DC Dale, DD Federman, eds., ACP Medicine, section 12, chap. 9. New York: Web MD.

6. National Cancer Institute (2006): Prostate Cancer (PDQ): Treatment—Health Professional Version. Available online: http://www.nci.nih.gov/cancertopics/pdq/treatment/prostate/HealthProfessional.

7. Calle EE, et al. (2003). Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. New England Journal of Medicine, 348(17): 1625–1638.

8. Rodriguez C, et al. (2001). Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiology, Biomarkers and Prevention, 10(4): 345–353.

9. Reiter RE, deKernion JB (2002). Epidemiology, etiology, and prevention of prostate cancer. In PC Walsh et al., eds., Campbell's Urology, 8th ed., vol. 4, pp. 3003–3024. Philadelphia: W.B. Saunders.

10. Brigitte L, et al. (2004). Nonhormonal alternatives for the treatment of hot flashes. Pharmacotherapy, 24(1): 79–93.

11. McNeel DG, Malkovsky M (2005). Immune-based therapies for prostate cancer. Immunology Letters, 96(1): 3-9.

12. Bader P, et al. (2003). Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? Journal of Urology, 169(3): 849–854.

13. Foley KM (2005). Management of cancer pain. In VT DeVita Jr et al., eds., Cancer: Principles and Practice of Oncology, 7th ed., pp. 2615–2649. Philadelphia: Lippincott Williams and Wilkins.

14. Shahinian VB, et al. (2005). Risk of fracture after androgen deprivation for prostate cancer. New England Journal of Medicine, 352(2): 154–164.

15. Hellerstedt BA, Pienta KJ (2002). The current state of hormonal therapy for prostate cancer. CA—A Cancer Journal for Clinicians, 52(3): 154–179.

Other Works Consulted

• Das P, Kaplan I (2002). The role of PC-SPES, selenium, and vitamin E in prostate cancer. Oncology 16(3): 285–300.

• Michaelson MD, et al. (2004). Prostate cancer (metastatic). Clinical Evidence (11): 1159–1168.

Go to previous section	Go to top of page	Go to next section
Author:	Kathe Gallagher, MSW	Last Updated: July 24, 2006
Medical Review:	Martin Gabica, MD - Family Medicine Christopher G. Wood, MD, FACS - Urology/Oncology
© 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.